Tylenol vs. advil: which is safer for period cramps in Crohn's?

NCT ID NCT07337902

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing how well two common pain relievers—acetaminophen (Tylenol) and ibuprofen (Advil)—work for period cramps in women with Crohn's disease. Twenty-four women will take each drug for two menstrual cycles and report their symptoms. The main goal is to see if a larger, more definitive study is possible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

acetaminophen and ibuprofen

What this could lead to

If successful, this pilot could pave the way for a larger study that helps determine which painkiller is safer and more effective for period cramps in women with Crohn's disease.

What could go wrong

This is a very small pilot study (24 people) focused on feasibility, not on proving which drug works better. Results may not apply to all women with Crohn's disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSMENORRHEA PRIMARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease primary dysmenorrhea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of North Carolina at Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••